For patients with late-stage pancreatic or liver cancer, the clinical conversation is often a grim one. Surgical resection may be off the table, and systemic chemotherapy can inflict a punishing toll for marginal gains. RadioClash, a Houston-based medical device startup founded in 2020, is betting that a different kind of physics can change that calculus. The company is developing the Electro-Embolizer Device (EED), a minimally invasive surgical probe designed to deliver electroporation therapy directly into solid tumors, aiming to make a notoriously difficult treatment more precise and less destructive [Voyage Houston Magazine].
A Physical Wedge Into Solid Tumors
The company's core technology, combination electroporation therapy (CET), is not a new concept. Electroporation uses short, high-voltage electrical pulses to create temporary pores in cell membranes. RadioClash's proposed innovation lies in combining this physical disruption with the localized delivery of small-molecule drugs, a one-two punch intended to kill cancer cells more effectively while sparing surrounding healthy tissue [Columbia Entrepreneurship, Nov 2021]. The procedure is designed for interventional radiologists, who would navigate the probe to the tumor site using imaging guidance. This positions the therapy within the growing field of interventional oncology, which seeks less invasive alternatives to open surgery. The initial targets are clear and daunting: pancreatic, liver, and bone cancers, where late-stage options are severely limited.
The Long Road From Lab to Clinic
The path from a prototype to a commercially available medical device is long, expensive, and heavily regulated. RadioClash's disclosed $1 million seed round, reported by SignalBase, is a start but represents early-stage capital in a field where bringing a device to market can cost tens or hundreds of millions [SignalBase]. The company has partnered with Biotex, a Houston medtech firm, for strategic guidance on commercialization, a common move for capital-constrained startups to access expertise [Columbia Entrepreneurship, Nov 2021]. What the public record lacks, however, are the critical milestones that define progress in this sector. There is no disclosed information on preclinical study results, an Investigational Device Exemption (IDE) submission to the FDA, or plans for clinical trials. These are the essential next steps that will determine whether the technology can transition from a compelling idea to a viable therapy.
The Team and the Traction Gap
The founding team brings a blend of medical and technical expertise. Dr. John Qiao, the CEO, is a physician, while Duane Bester serves as Chief Technology Officer [YouTube, Sep 2025] [Startup Columbia, 2022]. Their victory in the 2021 Columbia-CareOne Healthcare Innovation Challenge provided early validation and a $25,000 grant, but the years since have yielded little public evidence of commercial or clinical momentum [CareOne, 2021]. The competitive and regulatory landscape presents a formidable challenge.
| Competitor / Approach | Key Differentiator | Status / Challenge |
|---|---|---|
| Traditional Surgery & Radiation | Standard of care for resectable tumors. | Invasive, with significant morbidity; often not an option for advanced disease. |
| Systemic Chemotherapy / Immunotherapy | Whole-body treatment. | Limited efficacy in some cancers, high toxicity. |
| Other Ablation Technologies (e.g., RF, Microwave) | Established minimally invasive techniques. | Can cause collateral thermal damage to nearby structures. |
| Other Electroporation Devices | Non-thermal ablation mechanism. | Some devices are FDA-cleared for soft tissue; proving superiority in combination therapy is key. |
RadioClash's bet hinges on proving that its specific approach to combination therapy offers a meaningful improvement over existing ablation tools. A company video from late 2025 touted a projected 96% gross margin business model, a figure that remains unverified and speaks to a distant commercial future rather than present reality [YouTube, Sep 2025]. For now, the company's most tangible asset is its intellectual property and its focus on a dire patient need.
What Standard of Care Looks Like Today
For the patients RadioClash aims to serve, the current reality is harsh. The standard of care for late-stage pancreatic cancer, for instance, often involves aggressive combination chemotherapy regimens like FOLFIRINOX, which can extend life by several months but with severe side effects that drastically reduce quality of life. For liver cancers, options range from embolization procedures to targeted radiation, but five-year survival rates for advanced disease remain low. RadioClash's proposed therapy enters this space with a promise of localized precision, attempting to circumvent the systemic toll of chemotherapy. The clinical question, yet to be answered, is whether the electroporation-enhanced drug delivery is significantly more effective than drug delivery alone, and whether the safety profile justifies the procedural intervention.
The Next Twelve Months
RadioClash's immediate future will be defined by data and dollars. The watchpoints for the coming year are distinctly clinical and regulatory in nature.
- Preclinical Data. The first necessary signal will be the publication or presentation of robust preclinical data demonstrating safety and efficacy in animal models.
- Regulatory Strategy. The company must clarify its regulatory pathway, likely starting with a FDA Q-submission to discuss requirements for an IDE, which permits limited human testing.
- Financing. The $1 million seed is unlikely to fund a pivotal trial. Securing a Series A round, potentially from specialized healthcare VCs or strategic corporate investors, will be essential to reach the next milestone. The ambition is clear: to offer a new tool for some of oncology's most difficult battles. The journey from a Houston lab to a hospital procedure room, however, is a marathon of validation that RadioClash has only just begun.
Sources
- [Voyage Houston Magazine] Meet Dr. John Qiao of RadioClash | https://voyagehouston.com/interview/meet-john-qiao-m-d-of-radioclash-ltd-co/
- [Columbia Entrepreneurship, Nov 2021] RadioClash Wins Columbia-CareOne Healthcare Innovation Challenge | https://entrepreneurship.columbia.edu/2021/11/19/radioclash-wins-columbia-careone-healthcare-innovation-challenge-2021-columbia-venture-competition/
- [SignalBase] RadioClash, Inc. Secures $1M Seed Funding | https://www.leadsontrees.com/news/radioclash-inc-secures-1m-seed-funding
- [YouTube, Sep 2025] RadioClash Company Overview | https://www.youtube.com/watch?v=6XH8Pz3L_7U
- [Startup Columbia, 2022] General 1 | https://www.startupcolumbia.org/fall-2022-competition
- [CareOne, 2021] Winner Announced for the 2021 Columbia CareOne Healthcare Innovation Challenge | https://www.care-one.com/blog/winner-announced-for-the-2021-columbia-careone-healthcare-innovation-challenge/